Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
16 oct. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver...
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
12 juin 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
30 avr. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
08 janv. 2024 08h00 HE
|
Wave Life Sciences USA, Inc.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
06 déc. 2023 16h08 HE
|
Wave Life Sciences USA, Inc.
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size to Hit Around USD 2,517 Mn by 2032
27 mars 2023 02h27 HE
|
Market.Us
New York, March 27, 2023 (GLOBE NEWSWIRE) -- The global alpha-1 antitrypsin deficiency augmentation therapy market size accounted for USD 1,413 million in 2022 and growth is estimated to accelerate...
Global Alpha-1 Antitrypsin Deficiency (A1ATD) Treatment Market to Reach US$ 10 Billion by 2033; Growing at an Impressive 12.8% CAGR – Future Market Insights, Inc.
09 janv. 2023 06h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Jan. 09, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Alpha-1 Antitrypsin Deficiency market to augment at a 12.8% CAGR from 2023 to 2033. By the end of...
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel Therapeutic Assessment
12 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel...